Reuben McGregor
Overview
Explore the profile of Reuben McGregor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
537
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wilson N, Anderson A, Baker M, Bennett J, Dennison A, McGregor R, et al.
J R Soc N Z
. 2024 Dec;
55(2):241-266.
PMID: 39677380
This review summarises advances in research from Aotearoa, New Zealand (NZ) that have potential to reduce the inequitable distribution of acute rheumatic fever (ARF) and rheumatic heart disease (RHD). ARF...
2.
Lorenz N, James A, Van Rooyen T, Paterson A, Ramiah C, Carlton L, et al.
J Infect Dis
. 2024 Dec;
231(1):e77-e81.
PMID: 39673749
Surges in infections caused by respiratory pathogens have been documented in multiple settings after relaxation of pandemic restrictions. Antibodies to major antigens from respiratory syncytial virus and group A Streptococcus...
3.
Massai L, Carducci M, Rovetini L, Paterson A, Whitcombe A, McGregor R, et al.
J Immunol Methods
. 2024 Dec;
536():113786.
PMID: 39643029
Exposure to Group A Streptococcus leads to a broad spectrum of disease and sequelae, as the bacterium employs a wide range of virulence factors to facilitate colonization of the host,...
4.
Osowicki J, Frost H, Azzopardi K, Whitcombe A, McGregor R, Carlton L, et al.
Nat Commun
. 2024 Dec;
15(1):10506.
PMID: 39627204
Knowledge gaps regarding human immunity to Streptococcus pyogenes have impeded vaccine development. To address these gaps and evaluate vaccine candidates, we established a human challenge model of S. pyogenes pharyngitis....
5.
McGregor R, Paterson A, Lavender B, Hooker C, Frampton C, Wiig K, et al.
Vaccine
. 2024 Oct;
42(26):126482.
PMID: 39467412
The successive dominance of SARS-CoV-2 omicron sublineages presents challenges for vaccination strategies with respect to the antigenic content of boosters. New Zealand's COVID-19 elimination strategy (2020-2021) ensured the major vaccination...
6.
Lorenz N, McGregor R, Whitcombe A, Sharma P, Ramiah C, Middleton F, et al.
iScience
. 2024 Aug;
27(8):110558.
PMID: 39184444
Understanding the immune profile of acute rheumatic fever (ARF), a serious post-infectious sequelae of (group A [GAS]), could inform disease pathogenesis and management. Circulating cytokines, immunoglobulins, and complement were analyzed...
7.
McGregor R, Carlton L, Paterson A, Hills T, Charlewood R, Moreland N
Vox Sang
. 2023 Oct;
118(12):1145-1147.
PMID: 37817295
No abstract available.
8.
McGregor R, Paterson A, Sharma P, Chen T, Lovell J, Carlton L, et al.
mSphere
. 2023 Sep;
8(5):e0017923.
PMID: 37729548
Group A (GAS) is a leading human pathogen for which there is no licensed vaccine. Infections are most common in young children and the elderly suggesting immunity accumulates with exposure...
9.
Vidal-Seguel N, Cabrera C, Ferrada L, Artigas-Arias M, Alegria-Molina A, Sanhueza S, et al.
Exp Gerontol
. 2023 Sep;
181:112280.
PMID: 37659743
Neutrophil extracellular trap formation (NETosis) is a mechanism used by neutrophils to capture pathogens with their own DNA. However, the exacerbation of this immune response is related to serious inflammatory...
10.
Lavender B, Hooker C, Frampton C, Williams M, Carson S, Paterson A, et al.
Vaccine
. 2023 Jul;
41(38):5535-5544.
PMID: 37516574
The ability of a third dose of the Pfizer-BioNTech BNT162b2 SARS-CoV-2 vaccine to stimulate immune responses against subvariants, including Omicron BA.1, has not been assessed in New Zealand populations. Unlike...